NO311488B1 - Valaciclovir-tabletter inneholdende kolloidalt silisiumdioksyd, anvendelse av valaciclovir for fremstilling avtablett, samt fremgangsmåte for fremstilling av nevnte tablett - Google Patents

Valaciclovir-tabletter inneholdende kolloidalt silisiumdioksyd, anvendelse av valaciclovir for fremstilling avtablett, samt fremgangsmåte for fremstilling av nevnte tablett Download PDF

Info

Publication number: NO311488B1
Authority: NO; Norway
Prior art keywords: weight; tablet; valaciclovir; salt; lubricant
Prior art date: 1995-01-20

Application number

NO19973327A

Other languages

English (en)

Norwegian (no)

Other versions

NO973327L (no

NO973327D0 (no

Inventor

Barry Howard Carter

Lloyd Gary Tillman

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-20

Filing date

1997-07-18

Publication date

2001-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311488(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-07-18 Application filed by Wellcome Found filed Critical Wellcome Found

1997-07-18 Publication of NO973327D0 publication Critical patent/NO973327D0/no

1997-09-16 Publication of NO973327L publication Critical patent/NO973327L/no

2001-12-03 Publication of NO311488B1 publication Critical patent/NO311488B1/no

Links

VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims description 56
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title claims description 51
229940093257 valacyclovir Drugs 0.000 title claims description 48
238000000034 method Methods 0.000 title claims description 17
239000008119 colloidal silica Substances 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 5
239000000945 filler Substances 0.000 claims description 39
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 36
239000008187 granular material Substances 0.000 claims description 36
239000000314 lubricant Substances 0.000 claims description 36
150000003839 salts Chemical class 0.000 claims description 33
239000011230 binding agent Substances 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 24
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 12
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
229940069328 povidone Drugs 0.000 claims description 12
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
239000008108 microcrystalline cellulose Substances 0.000 claims description 10
229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 9
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
239000007884 disintegrant Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 5
238000005336 cracking Methods 0.000 claims description 4
230000001629 suppression Effects 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
229960000913 crospovidone Drugs 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
238000003825 pressing Methods 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
208000001688 Herpes Genitalis Diseases 0.000 claims description 2
201000004946 genital herpes Diseases 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
230000000306 recurrent effect Effects 0.000 claims description 2
235000012239 silicon dioxide Nutrition 0.000 claims description 2
238000005422 blasting Methods 0.000 claims 2
206010019972 Herpes viral infections Diseases 0.000 claims 1
238000013160 medical therapy Methods 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
239000003826 tablet Substances 0.000 description 75
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000003814 drug Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000004615 ingredient Substances 0.000 description 10
239000000843 powder Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
239000007916 tablet composition Substances 0.000 description 8
-1 L-valine ester Chemical class 0.000 description 7
229960004150 aciclovir Drugs 0.000 description 7
239000011928 denatured alcohol Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000002441 X-ray diffraction Methods 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229910002012 Aerosil® Inorganic materials 0.000 description 5
239000013543 active substance Substances 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000007888 film coating Substances 0.000 description 4
238000009501 film coating Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
238000005461 lubrication Methods 0.000 description 4
238000000634 powder X-ray diffraction Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
238000005096 rolling process Methods 0.000 description 3
238000005292 vacuum distillation Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 2
JILCEWWZTBBOFS-UHFFFAOYSA-N 4-(methylamino)antipyrine Chemical compound O=C1C(NC)=C(C)N(C)N1C1=CC=CC=C1 JILCEWWZTBBOFS-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
241000701027 Human herpesvirus 6 Species 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000010949 copper Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000011812 mixed powder Substances 0.000 description 2
239000012046 mixed solvent Substances 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
101000870363 Oryctolagus cuniculus Glutathione S-transferase Yc Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
238000005056 compaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000010354 integration Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960002614 lanatoside c Drugs 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000011164 primary particle Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000011163 secondary particle Substances 0.000 description 1
150000003377 silicon compounds Chemical class 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
208000010531 varicella zoster infection Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO19973327A 1995-01-20 1997-07-18 Valaciclovir-tabletter inneholdende kolloidalt silisiumdioksyd, anvendelse av valaciclovir for fremstilling avtablett, samt fremgangsmåte for fremstilling av nevnte tablett NO311488B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9501127.6A GB9501127D0 (en)	1995-01-20	1995-01-20	Tablet
PCT/GB1996/000111 WO1996022082A1 (en)	1995-01-20	1996-01-19	Valaciclovir tablets containing colloidal silicon dioxide

Publications (3)

Publication Number	Publication Date
NO973327D0 NO973327D0 (no)	1997-07-18
NO973327L NO973327L (no)	1997-09-16
NO311488B1 true NO311488B1 (no)	2001-12-03

Family

ID=10768317

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19973327A NO311488B1 (no)	1995-01-20	1997-07-18	Valaciclovir-tabletter inneholdende kolloidalt silisiumdioksyd, anvendelse av valaciclovir for fremstilling avtablett, samt fremgangsmåte for fremstilling av nevnte tablett

Country Status (38)

Country	Link
US (1)	US5879706A (pt)
EP (1)	EP0806943B1 (pt)
JP (1)	JP3350055B2 (pt)
KR (1)	KR100412298B1 (pt)
CN (2)	CN1313081C (pt)
AP (1)	AP666A (pt)
AT (1)	ATE190483T1 (pt)
AU (1)	AU710823B2 (pt)
BG (1)	BG63187B1 (pt)
BR (1)	BR9606769A (pt)
CA (1)	CA2210891C (pt)
CY (1)	CY2182B1 (pt)
CZ (1)	CZ296514B6 (pt)
DE (1)	DE69607146T2 (pt)
DK (1)	DK0806943T3 (pt)
EA (1)	EA000276B1 (pt)
EE (1)	EE03336B1 (pt)
ES (1)	ES2145425T3 (pt)
FI (1)	FI119722B (pt)
GB (1)	GB9501127D0 (pt)
GE (1)	GEP20022752B (pt)
GR (1)	GR3033677T3 (pt)
HU (1)	HU226131B1 (pt)
IL (1)	IL116830A (pt)
IN (1)	IN181318B (pt)
MY (1)	MY126346A (pt)
NO (1)	NO311488B1 (pt)
NZ (1)	NZ298846A (pt)
OA (1)	OA10500A (pt)
PL (1)	PL185307B1 (pt)
PT (1)	PT806943E (pt)
RO (1)	RO118175B1 (pt)
SK (1)	SK282030B6 (pt)
TR (1)	TR199700657T1 (pt)
UA (1)	UA68325C2 (pt)
UY (2)	UY25774A1 (pt)
WO (1)	WO1996022082A1 (pt)
ZA (1)	ZA96448B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet
ZA97400B (en) *	1996-01-19	1997-11-13	Glaxo Group Ltd	Valaciclovir.
AR017512A1 (es) *	1997-08-22	2001-09-12	Smithkline Beecham Corp	Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es)	1997-08-22	2001-08-01	Smithkline Beecham Corp	PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO2000037055A1 (en) *	1998-12-18	2000-06-29	Abbott Laboratories	Controlled release formulation of divalproex sodium
GB0010446D0 (en) *	2000-04-28	2000-06-14	Glaxo Wellcome Kk	Pharmaceutical formulation
EP1383482B1 (en) *	2001-05-01	2007-07-18	Pfizer Products Inc.	Method for manufacturing a low dose pharmaceutical composition
US7815936B2 (en) *	2001-10-30	2010-10-19	Evonik Degussa Gmbh	Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003040145A1 (en) *	2001-11-05	2003-05-15	Glaxo Group Limited	Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) *	2001-11-14	2010-01-19	Teva Pharmaceutical Industries Ltd.	Synthesis and purification of valacyclovir
GB0203296D0 (en) *	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
US20060147519A1 (en) *	2002-06-24	2006-07-06	Ashish Gogia	Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) *	2002-09-20	2005-03-10	Avinash Nangia	Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) *	2002-10-16	2005-03-17	Ben-Zion Dolitzky	Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ATE335743T1 (de) *	2002-10-16	2006-09-15	Teva Pharma	Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
US20040109889A1 (en) *	2002-12-04	2004-06-10	Bunick Frank J.	Surface treatment composition for soft substrates
AU2003232719A1 (en) *	2003-05-30	2005-01-21	Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S.	Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) *	2003-06-02	2005-01-06	Teva Pharmaceutical Industries, Ltd.	Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) *	2003-07-15	2009-12-15	Eurand, Inc.	Controlled release potassium chloride tablets
PT2821067T (pt)	2003-09-12	2017-12-01	Amgen Inc	Formulação de cinacalcet de dissolução rápida
DE10351448A1 (de) *	2003-11-04	2005-06-09	Bayer Healthcare Ag	Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
EP1541133B1 (en) *	2003-12-09	2005-08-10	Helm AG	Pharmaceutical formulation of valaciclovir
US7344907B2 (en) *	2004-11-19	2008-03-18	International Business Machines Corporation	Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko)	2004-12-06	2012-02-22	에스케이케미칼주식회사	안정성이 개선된 말레인산 암로디핀 약제 조성물
WO2006094626A1 (en)	2005-03-07	2006-09-14	Bayer Healthcare Ag	Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2006127217A2 (en) *	2005-05-25	2006-11-30	Eli Lilly And Company	Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) *	2005-07-21	2007-01-24	SOLMAG S.p.A.	Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) *	2006-02-06	2007-08-16	Fidia Pharmaceutici S.P.A.	Solid formulations of valacyclovir hydrochloride
WO2007128350A1 (en) *	2006-05-10	2007-11-15	Evonik Degussa Gmbh	Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
PL2037887T3 (pl) *	2006-05-31	2011-03-31	Vertex Pharma	Doustne preparaty o kontrolowanym uwalnianiu inhibitora enzymu konwertującego interleukinę 1 beta
EP2040684B1 (en) *	2006-07-11	2013-01-23	LEK Pharmaceuticals d.d.	Multiple unit tablets
US20080167325A1 (en) *	2006-12-27	2008-07-10	Bs Praveen Kumar	Valacyclovir compositions
US20090076039A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched valacyclovir
ITRM20080027A1 (it) *	2008-01-18	2009-07-19	Maria Balestrieri	Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) *	2008-11-14	2010-05-20	Mcneil Ab	Multi portion intra-oral dosage form and use thereof
NZ595071A (en) *	2009-03-13	2013-01-25	Toyama Chemical Co Ltd	Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CH703348A1 (de) *	2010-06-29	2011-12-30	Mepha Gmbh	Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) *	2013-06-24	2014-12-31	Kraft Foods R & D Inc	Soluble Beverage Ingredients
KR101497508B1 (ko) *	2013-12-20	2015-03-03	한국유나이티드제약 주식회사	펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) *	2018-09-07	2020-03-12	Jubilant Generics Limited	Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) *	2019-07-30	2023-02-10	珠海润都制药股份有限公司	一种盐酸伐昔洛韦片及其制备方法
EP4157221A4 (en) *	2020-06-01	2024-07-24	Shilpa Medicare Limited	RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE
AU2021392532B2 (en) *	2020-12-01	2025-04-10	Lg Chem, Ltd.	Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
US20240091231A1 (en) *	2022-08-31	2024-03-21	Astrazeneca Ab	Pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1259924A (en) *	1985-03-25	1989-09-26	Wallace E. Becker	Pharmaceutical tableting method
AP55A (en) *	1987-08-15	1989-09-26	The Wellcome Foundation Ltd	Therapeutic Acyclic Nucleosides
DE68903605T2 (de) *	1988-05-04	1993-04-01	Smith Kline French Lab	Kautablette.
DK0522128T3 (da) *	1991-01-30	1996-02-26	Wellcome Found	Vanddispergerbare tabletter indeholdende acyclovir
GB9109862D0 (en) *	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
GB9317146D0 (en) *	1993-08-18	1993-10-06	Wellcome Found	Therapeutic combinations
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet

1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
1996
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown

Also Published As

Publication number	Publication date
BG63187B1 (bg)	2001-06-29
NZ298846A (en)	1998-06-26
UY25774A1 (es)	2000-10-31
AU4453496A (en)	1996-08-07
EP0806943A1 (en)	1997-11-19
EP0806943B1 (en)	2000-03-15
ATE190483T1 (de)	2000-04-15
CA2210891A1 (en)	1996-07-25
CN1131026C (zh)	2003-12-17
BG101831A (en)	1998-04-30
JP3350055B2 (ja)	2002-11-25
BR9606769A (pt)	1997-12-30
UA68325C2 (en)	2004-08-16
TR199700657T1 (xx)	1998-02-21
CN1179100A (zh)	1998-04-15
HU226131B1 (en)	2008-05-28
CY2182B1 (en)	2002-08-23
IL116830A0 (en)	1996-05-14
SK282030B6 (sk)	2001-10-08
AU710823B2 (en)	1999-09-30
SK96497A3 (en)	1998-01-14
MY126346A (en)	2006-09-29
NO973327L (no)	1997-09-16
KR19980701524A (ko)	1998-05-15
UY25778A1 (es)	2000-08-21
CA2210891C (en)	2009-05-19
FI973062L (fi)	1997-09-18
CN1494898A (zh)	2004-05-12
PT806943E (pt)	2000-08-31
HUP9801872A2 (hu)	1999-10-28
PL321361A1 (en)	1997-12-08
FI973062A0 (fi)	1997-07-18
GB9501127D0 (en)	1995-03-08
PL185307B1 (pl)	2003-04-30
EA199700123A1 (ru)	1997-12-30
US5879706A (en)	1999-03-09
GR3033677T3 (en)	2000-10-31
GEP20022752B (en)	2002-08-26
IL116830A (en)	2000-02-29
DE69607146D1 (de)	2000-04-20
CN1313081C (zh)	2007-05-02
HK1002851A1 (en)	1998-09-25
MX9705459A (es)	1997-10-31
AP9701057A0 (en)	1997-10-31
EA000276B1 (ru)	1999-02-25
HUP9801872A3 (en)	2001-02-28
ZA96448B (en)	1996-08-07
JPH10512564A (ja)	1998-12-02
CZ296514B6 (cs)	2006-03-15
FI119722B (fi)	2009-02-27
EE03336B1 (et)	2001-02-15
DE69607146T2 (de)	2000-09-21
NO973327D0 (no)	1997-07-18
KR100412298B1 (ko)	2004-04-21
RO118175B1 (ro)	2003-03-28
OA10500A (en)	2002-04-10
CZ229297A3 (cs)	1998-02-18
AP666A (en)	1998-08-24
ES2145425T3 (es)	2000-07-01
WO1996022082A1 (en)	1996-07-25
IN181318B (pt)	1998-05-09
DK0806943T3 (da)	2000-07-24

Publication	Publication Date	Title
NO311488B1 (no)	2001-12-03	Valaciclovir-tabletter inneholdende kolloidalt silisiumdioksyd, anvendelse av valaciclovir for fremstilling avtablett, samt fremgangsmåte for fremstilling av nevnte tablett
NO315558B1 (no)	2003-09-22	Vannfri krystallinsk form av valaciclovir-hydroklorid
AU2017241530B2 (en)	2022-12-15	Granulate formulation of 5-methyl-1-phenyl-2(1H)-pyridone and method of making the same
AU722304B2 (en)	2000-07-27	Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
EP1490034A1 (en)	2004-12-29	Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
MXPA97005459A (en)	1998-07-03	Valaciclovir tablets containing silicon dioxide color
HK1002851B (en)	2000-09-08	Valaciclovir tablets containing colloidal silicon dioxide
JP2025161976A (ja)	2025-10-24	イストラデフィリン製剤

Legal Events

Date	Code	Title	Description
2011-09-05	MM1K	Lapsed by not paying the annual fees